Acetaminophen Overdoses: A Review of Intentional and Unintentional Cases Hospital of the University of Pennsylvania Philadelphia, PA Sarah Erush, PharmD,

Slides:



Advertisements
Similar presentations
TRI science addiction Lost Opportunity? SBI for Substance Abuse In ERs and Trauma Centers Academy Health Mady Chalk, Ph.D. Treatment Research Institute.
Advertisements

Viha.ca Excellent care for everyone, everywhere, every time.
NAUSEA AND VOMITING OF PREGNANCY 제일병원 주산기 전임의 안계형.
Renal Protection for Coronary Angiography in Advanced Renal Failure Patients by Prophylactic Hemodialysis Presented by Mike Touchy, HO-I.
Tylenol and Hepatotoxicity Emmanuelle Mirsakov Pharm.D. Candidate 2007 USC School of Pharmacy
+ Case Study One Pediatric Patient’s Experience Shelley Chapman RN, BSN, CCTC Children’s Hospital of Wisconsin.
Acute Liver Failure in the USA: Results of the US ALF Study Group William M. Lee, MD Meredith Mosle Distinguished Professor in Liver Disease University.
Medication Reconciliation in Continuing Care Getting It Right Together Creating a Culture of Safety September 8, 2008 Dr. Paula Creighton MD, FRCP(C) Geriatric.
Safety Review for Plan B Daniel Davis, MD, MPH Division of Reproductive/Urologic Drugs.
Hallauer 06/20011 Outcome evaluation of an universal hepatitis B immunisation programme Johannes F. Hallauer M.D. Health Systems Research Charité, Humboldt.
BLOOD BORNE PATHOGEN EXPOSURE Management – What you need to know about Needlesticks and Splashes Amy J. Behrman, MD Occupational Medicine Dept of Emergency.
ICU Clinical Information Management System An Investigation for a Pediatric Intensive Care Unit Steven Sousa Ann Thompson.
Opioid Call History Utah Poison Control Center Marty Malheiro, MS, CHES Coordinator, Outreach Education.
Prescription Opioid Use and Opioid-Related Overdose Death — TN, 2009–2010 Jane A.G. Baumblatt, MD Centers for Disease Control and Prevention Epidemic Intelligence.
Postmarketing Risk Assessment of Drug Products Division of Drug Risk Evaluation Office of Drug Safety Center for Drug Evaluation and Research.
Basic Pharmacovigilance Training
Joint NDAC/PAC meeting October 18, 2007 OTC Cold and Cough Products: Use in Children Advisory Committee Meeting October 18, 2007 Joel Schiffenbauer, MD.
The Contribution of Mental Health Services to Tackling Health Inequalities Dr Alastair Cook Chair RCPsych in Scotland.
The Risks of Cough/Cold Preparations to Young Children Michael Shannon, MD, MPH Children’s Hospital Boston Harvard Medical School.
AA-7-1 René Belder, MD Executive Director Clinical Development and Life Cycle Management Cardiovascular / Metabolics 7asdf.
Overview of Acetaminophen Label Warnings William E. Gilbertson, PharmD. Division OTC Drug Products 1.
Measuring Output from Primary Medical Care, with Quality Adjustment Workshop on measuring Education and Health Volume Output OECD, Paris 6-7 June 2007.
CPRS/Pharmacy Laboratory Monitoring Project
Intensive versus Conventional Glucose Control in Critical Ill Patients N Engl J Med 2009; 360: 雙和醫院 劉慧萍藥師.
MCA Risk:benefit analysis of Kava-kava Update as at 12 Feb 2002.
Copyright (c) Pearson Education 2010 Drugs, Behavior, and Modern Society SIXTH EDITION Charles F. Levinthal Chapter 2 Drug-taking Behavior: The Personal.
PHARMACOVIGILANCE AND CLINICAL TRIALS DIVISION 20 August 2015 Victoria Falls Protecting Your Right to Quality Medicines and Medical Devices.
By Ameya Nerurkar Mandar Samant Chih-Pin Hsiao
CTD, Safety Tanja Braakman Genzyme Europe BV Pharmacovigilance Department.
Assessment of Efficacy and Safety for Exanta (Ximelagatran) Ruyi He, M.D. Medical Team Leader The Division of Gastrointestinal and Coagulation Drug Products.
DRAFT SLIDES FOR NDA ADVISORY COMMITTEE PRESENATIONS.
Corticosteroid dosing in the treatment of acute exacerbations of COPD Kurt A. Wargo, Pharm.D., BCPS, Takova D. Wallace, Pharm.D. Candidate 2014, Ryan E.
Acetaminophen Toxicity. Overview Principle pf the disease Clinical features Diagnosis Management.
Evaluation of intravenous acetaminophen use in a large community hospital Andrew R. Mameli, Pharm.D. Candidate, Nicholas L. Massie, Pharm.D., Richard L.
VIOXX ™ Gastrointestinal Outcome Research (VIGOR) Arthritis Advisory Committee Meeting February 8, 2001 Lourdes Villalba, M.D. DAAODP, CDER, FDA.
TARGET and TACTICS Clinical Trial Commentary Dr Eric Topol Chairman and Professor, Department of Cardiology Director of the Joseph J Jacobs Center for.
ALI R. RAHIMI, BOBBY WRIGHTS, MD, HOSSEIN AKHONDI, MD & CHRISTIAN M. RICHARD, MSC Clinical Correlation Between Effective Anticoagulants & Risk of Stroke:
Prevalence of Polypharmacy Exposure Among Hospitalized Children in the United States Feudtner C, Dai D, Hexem KR, Luan X, Metjian TA. Prevalence of polypharmacy.
COMET: Carvedilol Or Metoprolol European Trial Purpose To compare the effects of carvedilol (a β 1 -, β 2 - and α 1 -receptor blocker) and short-acting.
Review of Reported Adverse Events and Poisonings Associated with Cough and Cold Products in Young Children Joint Meeting of the Nonprescription Drugs Advisory.
Good Pharmacovigilance Practices
OTC NSAID and ASA GI Bleeding Analysis of Spontaneous Reports Nonprescription Drugs Advisory Committee Meeting Joyce P. Weaver, Pharm.D. Office of Drug.
Lesson 4Page 1 of 27 Lesson 4 Sources of Routinely Collected Data for Surveillance.
Nonprescription Drugs Advisory Committee Meeting Charles J. Ganley, M.D. Division of OTC Drug Products September 19, 2002.
Improving the agenda for Advertising and Switching for Nonprescription products Advancing Self-Care and Responsible Self-Medication for a Healthier Future.
1 Joint NDAC/EMDAC Meeting January 13, 2005 Mevacor TM Daily 20 mg Tablets Rx-to-OTC Switch Daiva Shetty, M.D. Division of Over-the-Counter Drug Products.
PROPER DISPOSAL OF UNWANTED MEDICATIONS “THE DISPOSAL PROPOSAL” Patti Darbishire, PharmD Clinical Associate Professor, Pharmacy Practice.
Outpatient Center. West Baltimore Chronic Disease Profile and Acute Care Utilization.
Acetaminophen Intoxication Ali Labaf M.D. Assistant professor Department of Emergency Medicine Tehran University of Medical Science.
Western Node Collaborative Capital Health MEDICATION RECONCILIATION Edmonton, Alberta Suburban / Rural Communities & Sturgeon Community Hospital.
COMPARISON OF ADVERSE EFFECT PROFILES OF PAIN REGIMENS WITH AND WITHOUT INTRAVENOUS ACETAMINOPHEN IN TOTAL HIP AND KNEE ARTHROPLASTY PATIENTS Alyssa J.
Risk Factors for Candida dubliniensis Bloodstream Infections Katherine Veltman, B.S., Peggy L. Carver, Pharm.D, FCCP The University of Michigan Health.
Risk Factors for Linezolid-Associated Thrombocytopenia in Adult Patients Cristina Gervasoni Ospedale Luigi Sacco, Milano.
The Effects of Intravenous Acetaminophen Use on Robot-Assisted Pelvic Surgery Patients Nichole Witmyer, Pharm.D. St. Dominic Hospital Jackson, Mississippi.
Seizure Incidence Associated with Bupropion Dosing Errors Reported to a Local Poison Center William Eggleston, PharmD 1 and Ross W. Sullivan, MD 1,2 1.
Drug Induced Liver Disease Tutoring
By: DR.Abeer Omran Consultant pediatric infectious disease
Documentation of pharmaceutical care
Acetylcysteine for Acetaminophen Poisoning
Cover slide.
Phase 3 Treatment-Naïve and Treatment-Experienced
8. Causality assessment:
Medications.
Medication Reconciliation in Continuing Care
Acetaminophen induced Acute Liver Failure
Protective Factors Screening
Influenza Vaccine Effectiveness Against Pediatric Deaths:
Calculating and Using Morphine Equivalent Doses of Opioids
Deprescribing Calcium-Based Phosphorus Binders in Dialysis Patients
Phase 3 Treatment-Naïve and Treatment-Experienced
Presentation transcript:

Acetaminophen Overdoses: A Review of Intentional and Unintentional Cases Hospital of the University of Pennsylvania Philadelphia, PA Sarah Erush, PharmD, BCPS Karen Shalaby, PharmD

Hospital of the University of Pennsylvania 700 bed tertiary academic medical facility Level I Trauma Center/Transplant Services Serves tri-state region Averages 35,000 admissions per year No pediatric admissions

Adverse Drug Event Program Operated by Drug Information Service Averages 600 reports per year Spontaneous and targeted reporting methods Acetaminophen overdoses reported despite recommendations otherwise Unintentional overdose trend noted

Acetaminophen Case Series 1998 – 2002 YTD 54 Reports 52 Charts Received 49 Reviewed 47 Acetaminophen 23 Intentional 23 Unintentional 1 unknown 3 Incomplete 2 Not Acetaminophen

Psychiatry Consult Service 13/23 (56%)0/23 (0%)No Request: 10/23 (44%)23/23 (100%)Request: UNINTENTIONALINTENTIONAL

Patient Demographics

Acetaminophen Dose 1.1 to to 101Range (gm/day) Median (gm/day) 8.132Average (gm/day) 8/23 (34%)10/23 (43%)Known 15/23 (65%)13/23 (56%)Unknown UNINTENTIONALINTENTIONAL

Acetaminophen Formulation INTENTIONAL RX = 3 Percocet  n=2 Darvocet  n=1 OTC =21 Single Entity n=8 Combo Entity n=13 UNINTENTIONAL RX = 3 Percocet  n=2 Darvocet  n=1 OTC = 20 Single Entity n=15 Combo Entity n=5

Causality: Unintentional Cases

Acute Exposure (< 7 days)

Lab Results: Average Peak Levels INTENTIONALUNINTENTIONAL APAP:115.1 mg/L27.8 mg/L ALT:3,065 units/L5,193 units/L AST:2,742 units/L6,819 units/L INR:2.54 T Bili:1.87 mg/dL5.87 mg/dL

Length of Stay 65Median 2 to 302 to 55Range TOTAL Days: Average 1 to 101 to 16Range 43Median ICU Days: Average UNINTENTIONALINTENTIONAL

Patient Outcome INTENTIONALUNINTENTIONAL Resolved:22/23 (96%)16/23 (69%) Evaluated:9/23 (39%)11/23 (48%) Transplant:0/23 (0%)2/23 (9%) Death:0/23 (0%)3/23 (13%) Transplant and Death: 1/23 (4%)0/23 (0%)

Risk Factors INTENTIONALUNINTENTIONAL Hepatic Disease:1/23 (4%)2/23 (9%) Alcohol Use: (Acute or Chronic) 14/23 (61%)20/23 (87%) Drug Abuse: (Current or Past) 10/23 (43%)8/23 (35%) Concomitant Disease: 1/23 (4%)3/23 (13%)

Alcohol Use 2/23 (9%)1/23 (5%)Unknown: 6/23 (26%)10/23 (44%)None: 6/23 (26%)3/23 (13%)Acute with Chronic: 0/23 (0%)2/23 (8%)Acute: 9/23 (39%)7/23 (30%)Chronic: UNINTENTIONALINTENTIONAL

Multiple Risk Factors

Data Summary Unintentional overdoses accounted for 50% cases Doses are lower and ingested over 1 to 3 days Unintentional cases had greater toxicity when judged by LFT, INR, and length of stay Unintentional cases had higher transplant and death rates

Data Summary cont. Influence of risk factors remains unclear Hospital Costs (mean) Intentional: $12,671 Unintentional: $23,380 Extrapolated Cost Data Results similar to those previously published

Recommendations Continue availability of OTC Acetaminophen Education of healthcare practitioners Encourage reporting of acetaminophen overdoses Awareness of unintentional overdoses Education of patients Awareness of potential toxicity

Recommendations cont. Labeling Maximum dose and duration Combination products Packaging Limit purchase size Consider unit dose application Manufacturing Consider addition of N-Acetylcysteine to Acetaminophen preparations.

Quote “If I had known it would make me this sick, I never would have taken it”